Cargando…

Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl

BACKGROUND: The log linear association between on-treatment LDL-C levels and ASCVD events is amplified in higher risk patient subgroups of statin versus placebo trials. OBJECTIVES: Update previous systematic review to evaluate how the log linear association influences the magnitude of cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, Jennifer G., Jayanna, Manju Bengaluru, Bairey Merz, C. Noel, Stone, Neil J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595281/ https://www.ncbi.nlm.nih.gov/pubmed/33119602 http://dx.doi.org/10.1371/journal.pone.0240166

Ejemplares similares

The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL
por: Li, Chuang, et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

The evaluation and management of patients with LDL-C ≥ 190 mg/dL in a large health care system
por: Jackson, Candace L., et al.
Publicado: (2020)

Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl"
por: Brown, W Virgil
Publicado: (2001)

A vasodilator stress MRI perfusion study: large HDL particle number is independently associated with microvascular function in patients with LDL-C <100mg/dL
por: Narang, Akhil, et al.
Publicado: (2013)

Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDL Cholesterol in Japanese Subjects with TG Levels <400 mg/dL
por: Moriyama, Kengo, et al.
Publicado: (2016)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
por: Krähenbühl, Stephan, et al.
Publicado: (2016)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
por: Clem, James R, et al.
Publicado: (2009)

Transiently Elevated TC and sdLDL-C Levels and Falsely Low LDL-C Levels in Patients with Extrahepatic Cholangiocarcinoma
por: Guo, Yi, et al.
Publicado: (2021)

LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone
por: Enomoto, Mika, et al.
Publicado: (2011)

Evaluation of different formulas for LDL-C calculation
por: Vujovic, Ana, et al.
Publicado: (2010)

Evidence-based goals in LDL-C reduction
por: Soran, Handrean, et al.
Publicado: (2017)

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
por: Dent, Ricardo, et al.
Publicado: (2016)

The lack of association between different LDL‐C levels and oxidized LDL in patients with type 2 diabetes
por: Rabizadeh, Soghra, et al.
Publicado: (2023)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

The LDL-C/Apo B predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C
por: Jung, Hae Won, et al.
Publicado: (2023)

A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C
por: Liao, Fangxin, et al.
Publicado: (2015)

Trends in LDL-C and Non-HDL-C Levels with Age
por: Zhang, Peng, et al.
Publicado: (2020)

Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering
por: Sun, Peng, et al.
Publicado: (2021)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?
por: Baruch, Lawrence, et al.
Publicado: (2013)

Oxidative modifications of foetal LDL-c and HDL-c lipoproteins in preeclampsia
por: León-Reyes, G., et al.
Publicado: (2018)

MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy
por: Tian, Yong, et al.
Publicado: (2021)

LDL-C Concentrations and the 12-SNP LDL-C Score for Polygenic Hypercholesterolaemia in Self-Reported South Asian, Black and Caribbean Participants of the UK Biobank
por: Gratton, Jasmine, et al.
Publicado: (2022)

Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS
por: Jain, Madhur, et al.
Publicado: (2023)

oxLDL and eLDL Induced Membrane Microdomains in Human Macrophages
por: Wallner, Stefan, et al.
Publicado: (2016)

Electronegative LDL: A Circulating Modified LDL with a Role in Inflammation
por: Estruch, Montserrat, et al.
Publicado: (2013)

Precipitated sdLDL: An easy method to estimate LDL particle size
por: Fernández‐Cidón, Bárbara, et al.
Publicado: (2020)

Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential
por: Deng, Chang-Feng, et al.
Publicado: (2022)

LDL-C: lower is better for longer—even at low risk
por: Penson, Peter E., et al.
Publicado: (2020)

Clinical Validation of Eleven Formulas for Calculating LDL-C in Iran
por: Atabi, Fereshteh, et al.
Publicado: (2020)

Targets of statins intervention in LDL-C metabolism: Gut microbiota
por: Sun, ChangXin, et al.
Publicado: (2022)

Measured and genetic LDL-C and the risk of incident atrial fibrillation
por: Park, H, et al.
Publicado: (2023)

Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with ‘Normal’ LDL-C Levels
por: Superko, Harold, et al.
Publicado: (2022)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough
por: Shanes, Jeffrey G.
Publicado: (2011)

Commentary: Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential
por: Ravnskov, Uffe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u734ap4gch8k4q2ue57ctv59fq